The implementation of the PR and Ki67 biomarkers as prognosis tools, along with other clinical variables such as tumor stage and nodal status [60, 61], could provide enough information about treatment response and it could be used by physicians to readjust therapy. The gene discussed is MKI67; the disease is neoplasm.